From Seekingalpha · Biotech Beast · · 40s
Incyte Shares ESMO 2026 Data for Pancreatic, Colorectal, Ovarian Cancers
Incyte's ESMO 2026 data shows promise for pancreatic, colorectal, and ovarian cancer treatments.
In brief
Incyte's ESMO 2026 data shows promise for pancreatic, colorectal, and ovarian cancer treatments. Incyte presents ESMO 2026 data indicating potential benefits for three cancer treatments. Originally reported by Seekingalpha.
Incyte ESMO 2026 Data
Incyte Corporation presents promising ESMO 2026 data for three solid tumor pipeline assets, aiming to offset Jakafi's looming loss of exclusivity.
KRAS G12D Inhibitor 734
KRAS G12D inhibitor '734 shows competitive efficacy in pancreatic and colorectal cancer, with notable 37% response rate when used in combination in pre-treated colorectal cancer patients.
INCA33890 and CDK2 Inhibitor
INCA33890 confirms differentiated activity in colorectal cancer with liver metastasis, but phase 3 outcomes remain difficult to predict.
Here's the gist
Incyte presents ESMO 2026 data indicating potential benefits for three cancer treatments.
